{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+Alfa-2a+and+Ribavirin&page=2", "query": { "intervention": "Peginterferon Alfa-2a and Ribavirin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 150, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+Alfa-2a+and+Ribavirin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+Alfa-2a+and+Ribavirin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T20:53:20.182Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00336479", "title": "Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa 2a", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 263, "start_date": "2006-06", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2014-07-23", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00336479" }, { "nct_id": "NCT00394277", "title": "A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1175, "start_date": "2007-02", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00394277" }, { "nct_id": "NCT01485991", "title": "TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "TVR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 771, "start_date": "2012-02", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2016-04-26", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 32, "location_summary": "Bakersfield, California • San Diego, California • Aurora, Colorado + 29 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485991" }, { "nct_id": "NCT00758043", "title": "A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "telaprevir", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 540, "start_date": "2008-10", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00758043" }, { "nct_id": "NCT00085917", "title": "Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "Double dose pegylated interferon with weight based Ribavirin", "type": "DRUG" }, { "name": "standard dose pegylated interferon alfa -2a and ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2004-06", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2011-06-27", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085917" }, { "nct_id": "NCT00084279", "title": "CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InterMune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2004-04", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2009-07-03", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 1, "location_summary": "Brisbane, California", "locations": [ { "city": "Brisbane", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084279" }, { "nct_id": "NCT01030432", "title": "Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-650032", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 285, "start_date": "2010-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030432" }, { "nct_id": "NCT00028093", "title": "Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Peginterferon alfa-2a with Ribavirin", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2001-12", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2013-11-08", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028093" }, { "nct_id": "NCT01271790", "title": "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Tegobuvir (GS-9190)", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "Pegasys®", "type": "BIOLOGICAL" }, { "name": "Copegus®", "type": "DRUG" }, { "name": "Tegobuvir placebo", "type": "DRUG" }, { "name": "GS-9451 placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 245, "start_date": "2010-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 85, "location_summary": "Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01271790" }, { "nct_id": "NCT00627926", "title": "A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon Alfa 2a", "type": "BIOLOGICAL" }, { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1095, "start_date": "2008-03", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-10-08T20:53:20.182Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00627926" } ] }